Related Experiment Video
Updated: Apr 2, 2026
04:11
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
Published on: December 15, 2023
5.2K
Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low-Level Viraemia
Paul Y Kwo1, Laura E Telep2, Lai San Hong2,3
1Division of Gastroenterology and Hepatology, Stanford University, Palo Alto, California, USA.
Alimentary Pharmacology & Therapeutics
|April 1, 2026
Summary
Hepatitis B virus low-level viraemia (HBV-LLV) is linked to a higher risk of serious liver problems, including cirrhosis and liver cancer. This finding highlights the need for better risk assessment and earlier treatment for chronic HBV patients.
Area of Science:
- Hepatology
- Virology
- Epidemiology
Background:
- The clinical significance of low-level viraemia (HBV DNA ≤ 2000 IU/mL) in chronic hepatitis B virus (HBV) infection remains incompletely understood.
- The association between HBV low-level viraemia (HBV-LLV) and adverse liver outcomes requires further investigation.
Purpose of the Study:
- To investigate the relationship between HBV-LLV and the risk of subsequent liver-related events in patients with chronic HBV.
- To compare liver disease progression in patients with and without HBV-LLV.
Main Methods:
- Propensity score-matched cohorts of adult patients with chronic HBV-LLV and controls without HBV were identified using administrative claims data.
- Cox proportional-hazards models assessed the risk of cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC), and liver transplant.
- Incidence rates and 95% CIs were calculated for liver-related events in both cohorts.
Main Results:
- Patients with HBV-LLV exhibited a significantly higher risk of cirrhosis, hepatic decompensation, HCC, and a composite of these events compared to controls.
- This elevated risk persisted in sensitivity analyses, including subgroups without antiviral treatment.
- Findings were validated in an independent US claims dataset, confirming the association between HBV-LLV and increased liver disease risk.
Conclusions:
- Individuals with chronic HBV-LLV face a significantly elevated risk of liver-related events.
- Further research is warranted to develop strategies for risk stratification and early intervention, potentially including earlier antiviral therapy.
Related Concept Videos
01:25Hepatitis
40
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
40
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
335
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
335
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
258
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
258
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
346
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
346
01:26Diseases of the Liver and Gallbladder
2.3K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.3K
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
304
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
304